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Introduction: Impaired T cell function in sepsis is associated with poor outcome, but the mechanisms are unclear.
In cancer, arginase-expressing myeloid derived suppressor cells (MDSCs) deplete arginine, impair T cell receptor
CD3 zeta-chain expression and T cell function and are linked to poor clinical outcome, but their role during acute
human infectious disease and in particular sepsis remains unknown. Hypoarginemia is prevalent in sepsis. This study
aimed to determine whether neutrophils that co-purify with PBMC express arginase, and if arginine depletion
constrains T cell CD3 zeta-chain expression and function in human sepsis.
Methods: Using flow cytometry, cell culture, HPLC, arginase activity and mRNA detection, our study examined
whether neutrophils, with reduced buoyant density isolated in the Ficoll interface, metabolise L-arginine and
suppress T cell proliferation in sepsis. A total of 35 sepsis patients (23 with septic shock) and 12 hospital controls in a
tertiary referral hospital in tropical Australia were evaluated.
Results: Only sepsis patients had interphase neutrophils, neutrophils co-purifying with mononuclear cells (≤1.077
specific gravity). The percentage of interphase neutrophils in sepsis was proportional to sepsis severity and correlated
with plasma IL-6 concentrations. Ex vivo, sepsis-derived interphase neutrophils expressed arginase, metabolised
culture L-arginine and suppressed T cell proliferation and CD3 zeta-chain expression. In vivo, in septic shock there
was a longitudinal inverse association between interphase neutrophil number and CD3 zeta-chain expression. Depletion
or inhibition of interphase neutrophils in vitro restored zeta-chain expression and T cell function.
Conclusions: For the first time during an acute human infection, interphase neutrophils that express arginase
were found to circulate in sepsis, in proportion to disease severity. These neutrophil-MDSCs impair T cell CD3
zeta-chain expression and T cell function via L-arginine metabolism, and likely contribute to the T cell dysfunction
seen in sepsis. Modulation of neutrophil-MDSC or their downstream effects warrant consideration as targets for
novel adjunctive therapies in sepsis.Introduction
Sepsis is a systemic inflammatory response to infection
[1]. Despite improvements in its management, septic
shock has a mortality rate of 30 to 50% [2-4] and is a
leading cause of death in ICUs [2].
Although sepsis patients have high levels of inflam-
matory mediators, some components of their immune* Correspondence: Tonia.Woodberry@menzies.edu.au
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unless otherwise stated.system are strongly suppressed [5,6], and sepsis has been
described as an immunosuppressive disorder or a state of
immunoparalysis [7,8]. Clinical trials demonstrate that
anti-inflammatory and immunosuppressive therapies may
be harmful in sepsis and septic shock [9,10]. In vivo evi-
dence of T cell dysfunction in sepsis is demonstrated by
impaired delayed-type hypersensitivity [11] and cyto-
megalovirus and herpes simplex virus re-activation [12,13].
This is supported ex vivo by impaired T cell proliferation,
cytokine production [14], and lymphocyte apoptosis [15].
Loss of T cell function is associated with sepsis mortality
[14,16], other poor outcomes [15] and decreased resistancetd. This is an Open Access article distributed under the terms of the Creative
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suppression in sepsis remain incompletely understood.
Sepsis patients have decreased plasma concentrations
of L-arginine [18], a conditionally essential amino acid
critical for immune function and for surface expression
of a fully functional T cell receptor (TCR) [19]. The TCR
trans-membrane molecule consists of an antigen-specific
αβ heterodimer receptor coupled to invariant γδε and ζ
homodimer chains that mediate signal transduction - en-
abling T cell proliferation and cytokine secretion. In vitro
L-arginine depletion impairs T cell zeta-chain expression
and cell proliferation, which both recover when L-arginine
is restored [19,20]. Arginase or arginase-producing cells
also impair T cell zeta-chain expression through local de-
pletion of L-arginine [21,22]. Our previous characterisation
of reduced L-arginine levels in sepsis patients [18] led to
the hypothesis that T cell zeta-chain downregulation con-
tributes to T cell dysfunction in sepsis.
Myeloid-derived suppressor cells (MDSC) are a
heterogenous group of cells which can downregulate
T cell receptor zeta-chain expression. MDSC suppress
T cell activation and proliferation and have been described
in cancer patients [23], trauma patients [24], healthy vol-
unteers systemically challenged with endotoxin [25],
mouse models of sepsis [26] and other murine infections
[27,28]. In human peripheral blood two major subpopula-
tions of MDSC are described; granulocytic and monocytic.
Monocytic MDSC express CD14 and exert suppression
via arginase, iNOS and suppressive cytokines [29]. Gran-
ulocytic or neutrophil-MDSC express CD15 and may sup-
press via the production of arginase or reactive oxygen
species [29]. Activated neutrophil MDSC have been shown
to co-purify with peripheral blood mononuclear cells
(PBMC) after density gradient separation [24,30,31]. As
immature neutrophils have been reported in PBMC from
three patients with sepsis [32], we hypothesised that neu-
trophils co-purifying with PBMC in sepsis are activated
MDSC which suppress T cells via arginase.
Here we report that sepsis patients have impaired
T cell zeta-chain expression and patients with shock
have significantly more neutrophils co-purifying with
PBMC compared to sepsis patients without shock. These
low density neutrophils suppress T cell proliferation and
in vitro depletion restores T cell zeta-chain expression
and T cell proliferative capacity. Consequently, these cells
can be considered neutrophil-MDSC. These data provide
a mechanism for T cell dysfunction in adults with severe
sepsis and suggest the potential for adjunctive therapies
to restore T cell function and improve outcome.
Materials and methods
Cohort
Sepsis patients had suspected or confirmed infection,
the presence of two or more criteria for the systemicinflammatory response syndrome (SIRS) within the last
4 hours [1], and were classified as having septic shock,
or sepsis without shock. Septic shock was defined at the
time of enrolment as systolic blood pressure <90 mmHg
or a reduction ≥40 mmHg from baseline despite ad-
equate fluid resuscitation, or the need for vasopressors
to maintain these targets [1]. Sepsis severity was esti-
mated using the acute physiology and chronic health
evaluation (APACHE) II score from the first 24 hours of
admission and daily modified sequential organ failure
assessment (SOFA) score. Patients were enroled within
24 hours of ICU admission or within 36 hours of ward
admission. Control subjects were recruited from hospital
patients who had not met SIRS criteria within the last
30 days and who had no clinical or laboratory evidence
of inflammation or infection. Written informed consent
was obtained from all participants or next of kin. The
study was approved by the Human Research Ethics
Committee of Menzies School of Health Research and
the Department of Health and Community Services.
Blood collection, sample preparation and
lymphocyte counts
Venous blood was collected in lithium heparin tubes at
enrolment (day 0), days 2 to 4, and day 7 until discharge
from the hospital or death. Whole-blood differential white
cell counts were measured by Coulter Counter. Plasma
was separated within 30 minutes of collection and stored
at −80°C. To exclude ex vivo neutrophil density changes,
cells were separated within 2 hours of collection using
Ficoll-Hypaque™ Plus (GE Healthcare Biosciences, Uppsala,
Sweden) density gradient. Interphase cells (those at the
1.088 specific gravity interphase), including neutrophils
and/or PBMC, were either stained fresh or cryopreserved
in liquid nitrogen in 90% heat-inactivated foetal calf serum
(GIBCO, Invitrogen, USA) and 10% dimethyl sulfoxide
(Sigma, USA). Neutrophils collected from the interface of
Ficoll, that is, co-located with PBMC in the interphase
layer were termed interphase neutrophils. In a subset of
samples, polymorphonuclear neutrophils (PMN) were
collected from beneath the Ficoll-Hypaque™ Plus layer
(bottom fraction).
Leukocyte/cell preparation for microscopy
Cells separated by density gradient into the interphase
and bottom fractions were prepared for microscopy by
cytospin. Samples were prepared with a cell suspension
of 50,000 cells in 100 μL of plasma. Centrifugation was
performed in a Shandon cytospin 4 (Thermo Fisher
Scientific, Australia) for 8 minutes at 800 revolutions per
minute (rpm). Preparations were fixed with Quick Dip
Fixative (Fronine Australia) and stained with Quick Dip
(Fronine). Manual leukocyte differentiation was performed
using a Zeiss microscope.
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All longitudinal samples cryopreserved in liquid nitrogen
were thawed simultaneously and tested in a single ex-
periment. The proportion of interphase neutrophils in
total interphase cells was calculated in 23 out of 24 sep-
sis patients and all control patients. For cryopreserved
samples, media with 50 units/mL benzonase nuclease
(Novagen, Denmark) was used in thawing to reduce cell
clumping, and the interphase cells were immediately
stained and analysed. Freshly-isolated cells were exam-
ined to confirm quantification of neutrophils in fresh
versus thawed samples and to validate phenotypic and
functional analyses.
Antibodies to CD3, CD16, CD56, CD11b, CD15,
CD33, CD49d, CD54 and CD62L were sourced from
Biolegend (CA, USA); CD4, CD8, CD66b and CD14
from BD Biosciences (Pharmingen, CA, USA); and
CD155 from eBioscience (CA, USA). CD247 (Beckman
Coulter, Immunotech, USA) was used to measure CD3
zeta-chain expression in cells surface stained, fixed in
0.25% paraformaldehyde (Sigma) [33] and permeabilised
with 100 μg/mL digitonin (Cayman chemical company,
Michigan, USA) while kept on ice for 10 minutes. To
control for inter-experimental variation in CD3 zeta-
chain mean fluorescence, cells from a single donation,
from a healthy donor, were cryopreserved in aliquots and
one aliquot was thawed with every experiment to estab-
lish a normalization factor. All cryopreserved cells and a
proportion of freshly isolated cells were read on a FACS-
Calibur flow cytometer (Becton Dickinson Immunocy-
tometry Systems, MA, USA) and analysed using Flow
Jo software (Tree Star, Oregon, USA). Freshly-isolated
cells and some cryopreserved cells were analysed later
using a Gallios flow cytometer (Beckman coulter) and
Kaluza 1.2 for data analysis.
Isolation of interphase neutrophils and T cell
proliferation assays
Interphase neutrophils were enriched from total interphase
cells by labeling with CD66b FITC (BD Biosceinces)
followed by anti-fluorescein isothiocyanate (FITC) mag-
netic bead selection (MACS, Miltenyi Biotech, USA)
according to manufacturer’s instructions. Proliferation
assays were arranged in 96- or 48-well plates using a
minimum of 200,000 cells/well of either total interphase
(including interphase neutrophils) or after depletion of
CD66b + interphase neutrophils. For some experiments
isolated interphase neutrophils or PMN were added back
to cultures after CD66b-depletion. Proliferation was de-
termined by labeling cells with 100 μM carboxyfluores-
cein diacetate succinimidyl ester (CFSE, Invitrogen) and
stimulating with immobilized anti-CD3 (1 μg/mL OKT-3;
Biolegend) and soluble anti-CD28 (0.1 μg/mL CD28.2,
Biolegend) antibodies. Proliferation was measured 3 to4 days later by flow cytometry following surface staining
of T cells. Cell division was confirmed by stimulating cells
and on day 4 staining with Ki67 (BD Biosciences). Culture
experiments used custom-formulated Advanced RPMI
1640 (Formula number 07-5074EA, GIBCO, Invitrogen)
with L-arginine at 150 μM. The selective, competitive
and high-affinity inhibitor of arginase N-Hydroxy-nor-
L-arginine, diacetate salt (nor-NOHA) (Calbiochem,
CA, USA) was used at a final concentration of 50 μM
in culture as indicated. The peroxynitirite scavenger uric
acid (Sigma, USA), was added to culture at a final con-
centration of 500 μM.
mRNA detection of arginase I and II
We prepared total RNA from cell pellets using Qiagen
RNeasy Mini Kit (catalogue number 74104 Qiagen,
USA) following the manufacturer’s protocol. cDNA was pre-
pared using the High Capacity cDNA Reverse Transcription
Kit (Applied Biosystems catalogue number 436881 USA)
following the manufacturer’s protocol. Quantitative PCR for
arginase 1 and arginase 2 (and the control genes GAPDH and
HPRT1) was performed using TaqMan master mix and probes
from Applied Biosystems and following manufacturer’s proto-
col. Fold changes were calculated using the ΔΔct method. The
primers and probes were designed using Universal Probe
Library Assay Design Center on the Roche website [34]. The
probes were purchased from Roche Universal Probe Library,
and the primers were purchased from Integrated DNA
Technologies (IDT) (Additional file 1: Table S1).
Plasma L-arginine and arginase activity
Plasma L-arginine concentrations were measured by
high pressure liquid chromatography (HPLC; Shimadzu,
Kyoto, Japan) with UV (250 nm) and fluorescence (excita-
tion 250 nm, emission 395 nm) detection [35]. Plasma argi-
nase activity was measured using a radiometric assay, as
previously described, and reported as micromole/milliliter/
hour [36].
Plasma cytokine measurements
Concentrations of plasma IFN-γ, IL6 and IL10 were deter-
mined using a cytometric bead array (Human Th1/Th2
Cytokine Kit II, BD Biosciences Pharmingen, CA, USA)
and analysed using FCAP array version 1.0.1 (Soft Flow
Hungary for Becton Dickinson Biosciences). The lower
limits of detection (LLD) of the assay were 2.5 pg/mL for
IFN-γ and 10 pg/mL for IL6 and IL10.
Concentrations of plasma vascular endothelial growth
factor (VEGF) were determined using the R&D human
VEGF Quantikine® ELISA in accordance with the manu-
facturer’s instructions. The lower limit of detection was
31 pg/mL. Values below the lower limits of detection
(LLD) were assigned a value halfway between zero and
the LLD for statistical analysis.
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Groups for analysis were septic shock, sepsis without shock
and hospital controls. Continuous non-normal variables
were compared using the Mann-Whitney test. Correlation
was examined using Pearson’s test. Linear mixed-effects
models were used to examine longitudinal correlation. A
two-sided P-value <0.05 was considered significant. Ana-
lyses were performed using Stata version 10.0 (Stata Corp
TX, USA) and Prism version 5.01 (GraphPad Software).
Results
Participants
We initially studied cryopreserved PBMC only from 24
patients with sepsis and 12 hospital controls (Table 1),
enroled in a previously reported longitudinal study of
endothelial function in sepsis [37], that were representative
of the entire cohort in terms of age, gender, ethnicity and
disease severity. Fresh and cryopreserved samples from an
additional 11 septic shock patients (Table 2) were used for
cell separation studies at a later time.
Neutrophils co-purify with PBMC in septic shock patients
Interphase cells from septic shock patients collected after





Subjects, n 12 12
Age, years 52 (45 to 57) 45 (39
Male, n (%) 7 (58%) 6 (50
ATSI, n (%) 10 (83%) 7 (58
APACHE II score, day 0 20 (29 to 23) 8 (4 to
SOFA score, day 0 10 (4 to 10) 1 (0 t
Plasma L-arginine, μM 39 (25 to 53) 40 (21
Plasma IL-6, pg/mL 1433 (400 to 4290) 82 (42 t
Plasma IL-10 (pg/mL), median (range) 65 (5 to 9525) 5 (5 to
Plasma VEGF, pg/mL 89 (16 to 115) 79 (62 t
Plasma arginase, μmol/mL/hr 0.18 (0.1 to 0.23)* 0.19 (0.12
Interphase-neutrophils (%) 19.2 (4.4 to 29.5) 2.7 (1.5
Neutrophil × 103/μL 13.1 (7.2 to 19.4) 14.2 (11.4
Imm. granulocyte × 103/μL, median (range) 0.4 (0 to 11.8) 0 (0 to
Monocyte × 103/μL 0.45 (0.1 to 1.2) 0.65 (0.4
Lymphocyte × 103/μL 1.2 (0.5 to 2.1) 1.2 (0.8
Causative organism, n (%)
None cultured 5 (42%) 9 (75
Gram-positive bacteria 4 (33%) 2 (17
Gram-negative bacteria 3 (25%) 1 (8
Values show the median (interquartile range) unless stated otherwise. *n = 11, Inter
interphase layer (gated per Figure 1A). ATSI, Aboriginal or Torres Strait Islander; APA
failure assessment; VEGF, vascular endothelial growth factor; N/A, not assessed; ns,with reduced buoyant density (≤1.077 specific gravity),
referred to as interphase neutrophils. Flow cytometry
revealed a similar forward and side scatter profile
(representing size and granularity) for both the inter-
phase neutrophils and the polymorphonuclear neutro-
phils (PMN) recovered from below the Ficoll-Hypaque
layer (Figure 1A). Cryopreserved interphase cells from 12
septic shock patients, 12 non-shock sepsis patients, and
12 hospital controls (Table 1) were assessed for the pres-
ence of interphase neutrophils. Only sepsis patients had
detectable interphase neutrophils (≥10% of all viable
cells). Septic shock patients had significantly more inter-
phase neutrophils compared to sepsis patients without
shock, both on the day of enrolment (P = 0.02 Figure 1B)
and on day 2 (P = 0.05 Figure 1B). The interphase neu-
trophils in septic shock patients were a mix of bands
(immature) and segmented (mature) cells by microscopy
and were found at multiple, but not all, longitudinal time
points (Figure 1C and Additional file 2: Figure S1). De-
tailed phenotypic characterisation of interphase neutro-
phils in fresh and frozen samples revealed high expression
of the granulocyte markers CD66b (a glycosylphosphatidy-
linositol linked protein), CD15 (a carbohydrate structure),
and CD11b (an integrin expressed by monocytes andls
s no
ck





to 55) 49 (40 to 56) ns ns
%) 8 (67%) ns ns
%) 8 (67%) ns ns
14) <0.0001 N/A
o 2) <0.0001 N/A
to 48) 74 (65 to 88) ns <0.0001
o 302) 5 (5 to 5) <0.0001 <0.0001
72) 5 (5) 0.001 0.004
o 138) 51 (32 to 71) ns 0.03
to 0.26) 0.14 (0.09 to 0.16) ns ns
to 6.1) 1.5 (0 to 2.0) 0.02 0.001
to 16.6) 6 (4.0 to 9.6) ns 0.02
7.6) 0 (0 to 0) 0.05 N/A
to 1) 0.55 (0.5 to 0.7) ns ns




phase neutrophil (%) indicates the proportion of neutrophils in the total
CHE, acute physiology and chronic health evaluation; SOFA, sequential organ
not significant.
Table 2 Characteristics of additional sepsis patients
enroled for cell separation and functional studies
Sepsis with shock
Subjects, n 11
Age, years 50 (37 to 70)
Male, n (%) 11 (100%)
ATSI, n (%) 6 (55%)
APACHE II score, day 0 15 (13 to 20)
SOFA score, day 0 7 (6 to 8)
Causative organism, n (%)
None cultured 4 (36%)
Gram-positive bacteria 4 (36%)
Gram-negative bacteria 3 (27%)
ATSI, Aboriginal or Torres Strait Islander; APACHE, acute physiology and
chronic health evaluation; SOFA, sequential organ failure assessment.
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activation) (Figure 1D). Interphase neutrophils also ex-
pressed CD45RO (leukocyte common antigen), CD49d
(integrin) and intermediate levels of CD16 (the Fcγ III
receptor) (Figure 1D and Additional file 3: Figure S2).D
A B
Figure 1 Phenotypic characterisation of interphase neutrophils in sep
representative healthy control and interphase cells and PMN from a repres
(ii) interphase neutrophils and (iii) PMN. The proportion of interphase neutro
expressed as a percentage of all viable cells. (B) The proportion of interphas
patients with septic shock (n = 12), sepsis without shock (n = 12) and hospital
the median and interquartile range. (C) Microscopic identification of interphas
(D) Fluorescence-activated cell sorting (FACS) Calibur flow cytometric phenot
representative septic shock patient. The first peak represents background or n
expressed on paired non-cryopreserved interphase neutrophil and polymorph
longitudinal day-2 or day-3 sample). P-values were derived using a non-parameThe interphase neutrophils were negative or low for
CD33 (a transmembrane glycoprotein expressed on
monocytes and myeloid progenitors), CD62L (L-selectin)
or CD54 (ICAM-1), the major histocompatability com-
plex class II antigen HLA DR and the monocyte
markers CD14 and CD115 (colony stimulating factor -1
receptor) (Figure 1D and Additional file 3: Figure S2). In
only the fresh (non-cryopreserved) samples, the more
buoyant interphase neutrophils were compared to PMN
and found to express significantly more CD15, while
CD16 (total or the high population) was similarly ex-
pressed between both (Figure 1E). The lack of CD33
expression distinguishes these cells from most human
neutrophil-MDSC previously described [29] and inter-
mediate to high CD16 expression and the lack of CD62L
or CD54 distinguishes these cells from those previously
described to be induced by endotoxin challenge by Pillay
[25]. In total, the phenotype of the interphase neutrophil
fits that of a mature neutrophil [38], and in shock pa-
tients the percentage of interphase neutrophils correlated
with the mature PMN count derived from an automated
cell counter.E
C
sis patients. (A) Flow cytometric evaluation of interphase cells from a
entative septic shock patient. Gated regions illustrate: (i) monocytes,
phils was determined using flow cytometry by gating region ii, and
e neutrophils collected following gradient separation of blood from
controls (n = 12) on day 0 (enrolment) and day 2. Horizontal lines show
e cells in longitudinal samples from a representative septic shock patient.
yping of (i) monocytes, (ii) interphase neutrophils and (iii) PMN from a
egative staining. (E) Gallios median fluorescence intensity (MFI) of CD15
onuclear neutrophils (PMN) from four septic shock patients (three with a
tric analysis of the seven paired interphase neutrophil and PMN data points.
Darcy et al. Critical Care 2014, 18:R163 Page 6 of 12
http://ccforum.com/content/18/4/R163Numbers of interphase neutrophils correlate with low
CD3 zeta-chain expression
Cryopreserved cells collected longitudinally from patients
with septic shock, non-shock sepsis, and hospital controls
were tested to measure associations between sepsis disease
severity, T cell zeta-chain expression, and the percentage
of interphase neutrophils. To allow the direct comparison
of longitudinal sepsis and control samples, cells were cryo-
preserved and all samples from each patient run on the
same day with a zeta control that was run at every experi-
ment. Only cryopreserved cells were evaluated for T cell
zeta-chain allowing the direct comparison of longitudinal
sepsis and control samples within experiments.
On admission, septic shock and non-shock patients
had significantly reduced T cell zeta-chain expression
(Figure 2A). However, by day 2, non-shock patients
had recovered T cell zeta-chain expression, while septic
shock patients with interphase neutrophils had not
(Figure 2B). In six septic shock patients with a day-7
sample there was no significant recovery in T cell zeta-Figure 2 Inverse association between T cell zeta-chain expression and
expression ex vivo in patients with septic shock (n = 12), sepsis without sho
day 2, zeta-chain expression remained low in septic shock patients but rec
and interquartile range. (C) Inverse association between the proportion of
patients with septic shock (n = 11) on day 0. (D) Longitudinal ex vivo CD
of interphase neutrophils (right axis, empty circles) in three representativ
was statistically significant in a mixed effects model (P = 0.02).chain expression, suggesting continued immunosup-
pression for at least one week. In the septic shock
patients, there was a strong inverse correlation between
the number of interphase neutrophils and expression of
the T cell zeta-chain, both on admission (day 0 r = −0.87,
P = 0.0009; Figure 2C) and day 2 (r = −0.85, P = 0.004).
The inverse association between CD3 zeta-chain expres-
sion and the interphase neutrophil number identified in
cross-sectional samples was particularly evident in longi-
tudinal ex vivo samples from patients with septic shock
(Figure 2D). The ex vivo longitudinal inverse associ-
ation was statistically significant in a mixed effects model
(P = 0.02), suggesting that interphase neutrophils mediate
T cell suppression via downregulation of the CD3 zeta-
chain.
In all sepsis patients, there was a positive correlation
between the interphase neutrophil number and plasma
concentrations of IL-6 on the day of admission (day 0,
r = 0.62, P = 0.002). In contrast, there was no association
between plasma concentrations of VEGF on the day ofinterphase neutrophil number. (A) Gated T cell CD3 zeta-chain
ck (n = 12), and hospital controls (n = 12) on day 0 (enrolment). (B) On
overed for non-shocked patients. Horizontal lines show the median
ex vivo interphase neutrophils and T cell zeta-chain expression in
3 zeta-chain expression (left axis, filled circles) and the percentage
e patients with septic shock. This longitudinal inverse association
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sepsis patients (r = −0.04, P = 0.84).
In vitro culture experiments examined the direct effect
of interphase neutrophils on T cell CD3 zeta-chain ex-
pression. We used FITC-labelled antibodies to CD66b
and magnetic beads to isolate and enrich interphase
neutrophils (Figure 3A). In a different individual, isolated
CD66b cells (which contained 94% CD66b + interphase
neutrophils with 1.4% lymphocytes and 1.9% monocytes)
were then returned to CD66-depleted interphase cells at
increasing concentrations and cultured. Culture experi-
ments demonstrated an inverse association between
CD3 zeta-chain expression and the CD66b + interphase
neutrophils (Figure 3B). Culture data confirmed the in-
verse associations observed in ex vivo cross-sectional
(Figure 2C) and longitudinal (Figure 2D) samples, and
established that only the CD66b + interphase cells were
responsible. In culture supernatant, L-arginine consump-
tion increased with increasing numbers of interphase neu-
trophils (Figure 3B).A B
DC
Figure 3 Functional characterisation of interphase neutrophils in sep
CD66b + interphase neutrophils (CD66b+), and polymorphonuclear neutrop
septic shock patient. (B) Total interphase cells were depleted of interphase
neutorophils were returned at 6%, 22%, 66% and 94% to PBMC. After 48 ho
zeta-chain expression (left axis, filled circles) and culture L-arginine concent
gated only on T cells, from a representative severe sepsis patient (grey fill)
neutrophils (black solid line). Plots represent a minimum of 50,000 T cells p
(from bottom fraction, black dashed line) at a ratio of 1:2. Control, unstimula
and CD4 T cell and CD8 T cell division of interphase cells from severe sepsisInterphase neutrophils suppress T cell function in
septic shock
T cell proliferation experiments sought to determine
whether interphase neutrophils compromised T cell
division. CD66b + interphase neutrophils were depleted
from interphase cells using magnetic beads, and T cell pro-
liferation was tested following CD3 and CD28 stimulation,
either in the presence or absence of the CD66b + inter-
phase neutrophils. Presence of CD66b + interphase neutro-
phils suppressed T cell proliferation (Figure 3C and
Additional file 4: Figure S3), with both CD4+ and CD8+ T
cell division compromised (Figure 3D). The interphase
neutrophils were able to suppress the highly stimulatory T
cell responses elicited by plate-bound anti-CD3 plus sol-
uble anti-CD28. Suppression of proliferation was mediated
by only the interphase neutrophils that co-purify with the
PBMC and not the PMN (Figure 3C). While the number
of interphase neutrohpils appeared to determine the inhib-
ition of T cell division, heterogeneity was observed in the
timing (day) of suppression within individuals.sis. (A) Microscopic evaluation of total interphase cells, enriched
hils (PMN) (from the bottom fraction) from a single representative
neutrophils (leaving PBMC), and the enriched CD66b + interphase
urs of culture, there was an inverse association between gated T cell
rations (right axis, empty triangles). (C) Proliferation of interphase cells,
and enhanced proliferation (left shift) after depletion of interphase
er condition. Enhanced proliferation remained with addition of PMN
ted interphase cells are designated by the dotted line. (D) Lymphocyte
patients before and after CD66b + depletion.
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T cell suppression
We hypothesised that interphase neutrophils suppress
T cell function and CD3 zeta-chain expression via L-
arginine depletion. In proliferation assays, addition of
the arginase inhibitor nor-NOHA restored T cell division
(Figure 4A). Evidence for the specificity of the inhibition
of interphase neutrophil arginase included the lack of in-
hibition by nor-NOHA of T cell proliferation in cells
from control patients (none of which had interphase
neutrophils), and the inability of the peroxynitrite scav-
enger uric acid to inhibit T cell proliferation in cells
from sepsis patients. In addition, in longitudinal sepsis
samples, nor-NOHA increased T cell proliferation only
when interphase neutrophil function was demonstrated
(that is, only on day 2, when depletion of the neutrophil-
MDSC restored proliferation, Figure 4A day 2). NoFigure 4 Arginase expression by interphase neutrophils. (A) T cell pro
representative severe sepsis patient. At each time point, T cell responses w
arginase inhibitor (black hashed line), and after CD66b + interphase neutrop
interphase neutrophils- enhanced proliferation. On day 2, addition of the a
was observed on day 0 and 7 following depletion of interphase neutrophils
cells in the absence of stimulation are designated by the dotted line. (B)
interphase cells and the enriched interphase neutrophils at all longitudinal (
arginase 2 mRNA expression in total cells (filled circles) and the interphase n
healthy control. (C) In the same severe sepsis patient, arginase 1 mRNA exp
the enriched interphase neutrophils. Arginase 1 expression was only detectedincreased proliferation was observed on day 0 and 7 fol-
lowing depletion of interphase neutrophils, suggesting the
interphase neutrophils were inactive.
Arginase was not detected in the culture supernatant
of total interphase cells, or the enriched CD66b + inter-
phase neutrophils after 24, 48 or 96 hours incubation,
suggesting there was no cell lysis or arginase secretion.
Nor was there supernatant evidence that interphase neu-
trophils from sepsis patients produced cytokines (IL-2,
IL-4, IL-6, IL-10, TNF or IFNγ) when cultured in vitro
(unstimulated total cells or enriched CD66b + interphase
neutrophils).
Arginase expression by the sepsis interphase neutrophil
was confirmed by PCR. At all longitudinal time points
(in two individuals), interphase cells expressed arginase 2.
Arginase 2 mRNA levels were at least 10-fold higher in
septic shock cells than healthy controls (Figure 4B). Dataliferation in longitudinal (day 0, 2, 3, and 7) samples from a
ere measured in total interphase cells (grey fill), with addition of an
hil depletion (black solid line). Only on day 2 and 3, removal of
rginase inhibitor also increased proliferation. No increased proliferation
, suggesting the interphase neutrophils were inactive. Control interphase
In the same severe sepsis patient, mRNA was extracted from total
day 0, 2, 3, and 7) time points. The line graph shows the fold change in
eutrophils (open circles) relative to interphase cells (PBMC) from a
ression was evaluated at each time point in total interphase cells and
on day 3 in both total interphase cells and the interphase neutrophils.
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alone were predominantly responsible for the arginase 2
mRNA expression detected in the total interphase cells
(Figure 4B). Arginase 1 mRNA was also detected in total
interphase cells and the isolated interphase neutrophils, co-
inciding with the day of peak interphase neutrophil activity
(Figure 4C).
Discussion
This study is the first description of interphase neutro-
phils metabolising arginine and constraining T cell func-
tion during an acute human infectious disease. Septic
shock patients have increased numbers of circulating
interphase neutrophils that downregulate expression of
T cell zeta-chain and suppress T cell function. Arginase-
mediated metabolism of L-arginine by these cells sup-
presses T cell proliferation; hence, these low-density
neutrophils are MDSC. Sepsis patients with higher num-
bers of circulating interphase neutrophil MDSC had
more severe disease, higher concentrations of plasma
IL-6 and slower recovery of T cell zeta-chain expression.
The slower recovery of T cell zeta-chain expression in sep-
tic shock patients is consistent with reports that patients
with more severe sepsis have longer durations of T cell dys-
function [5,14]. Slower recovery of T cell function appears
at least partially attributable to interphase neutrophil-
MDSC, suggesting these cells contribute to T cell dysfunc-
tion linked to greater risk of secondary bacterial infections
[17] and mortality in sepsis [14,16].
MDSC are evident in cancer and inflammatory bowel
disease [29], chronic hepatitis C [39], HIV [40], and
cystic fibrosis patients with chronic P. aeruginosa in-
fection [41], but there are no reports of them in any
acute human infectious disease, except in a few cases
of convalescent influenza [42]. MDSC have been de-
scribed in a mouse cecal ligation and puncture model
of sepsis where MDSC appear to improve survival
[43]. In contrast, our results from humans with sepsis
suggest that excessive numbers of circulating inter-
phase neutrophil MDSC may be harmful. Perhaps MDSC
that are activated to resolve inflammation blunt cel-
lular responses, enhancing susceptibility to secondary
infections [28,44]. This is consistent with studies that
show that impaired T cell function in septic shock is
associated with poor outcome [45]. Our sepsis data
also concur with data from cancer patients where in-
creased circulating MDSC are associated with more
aggressive disease [46].
This study is the first characterisation of diminished
T cell zeta-chain expression in human sepsis patients.
Downregulation of T cell zeta-chain is a frequent mech-
anism of immune suppression occurring in patients with
chronic hepatitis B, HIV, leprosy, lupus and cancer
[30,47-50] (see also review [51]).Although some human MDSC have staining pro-
files consistent with immature granulocytes [28], the
neutrophil-MDSC co-purifying with PBMC from sepsis
patients appear to be mature granulocytes. In particular,
high CD66b, high CD45RO and low CD33 expression are
all consistent with mature granulocyte staining [38], and
concur with the mature neutrophil phenotype described
in renal cell carcinoma patients [52] and in patients with
other advanced cancers [31]. The reduced buoyancy of the
interphase neutrophils in sepsis patients may represent
hyperactivated, degranulated mature granulocytes. Hypo-
dense granulocytes have been described in patients with
advanced cancer [31], renal cell carcinoma [30,52], cutane-
ous T-cell lymphoma [53], and trauma patients [24]. Pro-
inflammatory mediators, including IL-1ß, IL-6 and VEGF
can induce MDSC [54,55], and it was notable that inter-
phase neutrophils correlated with plasma IL-6 concentra-
tions, but not plasma VEGF concentrations in sepsis.
Perhaps the inflammatory environment of sepsis may con-
tribute to the accumulation of neutrophil-MDSC. Indeed
Schmeilau et al. demonstrated that PMN from a healthy
donor activated with N-formyl-L-methionyl-L-leucyl-L-
phenylalanine co-purify with PBMC and suppress T cells
in a dose-dependent manner [31]. In vivo, neutrophils
induced by acute inflammation, following LPS administra-
tion to volunteers, fulfil the role of MDSC and suppress
T cell proliferation [25].
The role of neutrophils in sepsis has long been contro-
versial with variations in their circulating number (high,
low, or with >10% of immature cells) and conflicting
reports concerning their functional status [56]. The in-
ability to distinguish PMN and interphase neutrophil-
MDSC in automated cell counts may have clouded the
interpretation of sepsis neutrophil data. While PMN are
beneficial through appropriate responsiveness to chemo-
tactic factors released by infection and bacterial phago-
cytosis, our data suggest that excessive induction of
neutrophil-MDSC will suppress T cell responses by
downregulating the zeta-chain compromising cellular
responsiveness. Interphase neutrophil-MDSC may repre-
sent a mechanism to sequentially downregulate T cell zeta-
chain and extinguish effector responses [57] during the
transition to memory cells. We speculate that neutrophil-
MDSC have a role in modulating T cell responses in sepsis,
but excessive numbers and prolonged detection appear to
contribute to greater disease severity.
Our initial use of cryopreserved samples precluded
direct comparisons between the atypical interphase neu-
trophils and the PMN. To compare suppressive capacity
of the neutrophil-MDSC and matched PMN, additional
patients were recruited and comparative assays on fresh
samples were done. Suppressive capacity was only de-
tected in the atypical interphase neutrophils. The role
of PMN, the triggering of neutrophil-MDSC and the
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further evaluation. Indeed further studies are warranted
to determine if interphase neutrophil-MDSC frequency,
duration or apoptosis/necrosis are predictors of patient
mortality.
Although we did not investigate associations be-
tween MDSC number and arginase mRNA, our re-
sults suggest that arginase is one mode of action of
interphase neutrophil-MDSC suppression in sepsis. Inter-
phase neutrophil-MDSC express arginase and consume
L-arginine, and the addition of an arginase inhibitor re-
stores T cell proliferation. Our inability to detect ar-
ginase in culture supernant suggests that arginase was
active internally in the interphase neutrophils and not
liberated in cell culture. These data are consistent with a
mechanism of suppression attributable to human MDSC
[54], and in particular, mature activated granuloctyes in
renal cell carcinoma [52].
Conclusion
In conclusion, we demonstrate that neutrophils which
co-purify with PBMC are MDSC that suppress T cell
proliferation by impairing T cell zeta-chain expression.
The percentage of interphase neutrophil MDSC in sepsis
patients is proportional to disease severity and correlates
with plasma IL-6 concentrations. Taken together, these
results suggest the inflammatory milieu of sepsis in-
creases circulating interphase neutrophil-MDSC, which
suppress T cell function. As in cancer [46], neutrophil-
MDSC are associated with more severe disease and may
be a major link between inflammation and T cell sup-
pression in sepsis. This study indentifies for the first
time neutrophil MDSC as mediators of impaired T cell
responses during acute human infection. A clear under-
standing of the role of interphase neutrophil-MDSC in
severe sepsis may help identify new targets for novel ad-
junctive treatment.
Key messages
 Hypodense neutrophils express arginase in sepsis
and suppress T cell function by decreasing
expression of the T cell zeta-chain.
 Patients with higher numbers of hypodense
neutrophils have more severe disease, higher plasma
IL-6 and slower recovery of T cell function.
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